---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088821"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:27:47.339492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25

## Summary
- FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.
- Cash $317.3M at June 30; raised ~$161.4M from July public offering; expects funding into end of 2024.
- Q2 2023 net loss $106.5M ($0.47/sh) vs $99.3M ($0.63/sh) in Q2 2022; R&D expense up to $86.3M.
- Revenue $0.2M from Proleukin acquisition in May 2023; no revenue in prior-year period.
- Registrational NSCLC trial IOV-LUN-202: 26.1% ORR in preliminary analysis; enrollment continuing.

## SEC filing metadata
- accession: 0001104659-23-088821
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/0001104659-23-088821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/tm2323093d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088821
- JSON: https://secwatch.observer/filing/0001104659-23-088821.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088821.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported financial results for second quarter and first half 2023.
  - Period: second quarter and first half 2023
  - Result: reported results
  source text: On August 8, 2023, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023 and an update on recent developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/0001104659-23-088821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.